Abstract
Background The use of blood eosinophil count (BEC) as a prognostic biomarker in the management of conditions such as asthma and chronic obstructive pulmonary disease (COPD) may be complicated by factors like atopy, age, sex, smoking, and comorbidities. Therefore, we aimed to produce reference values for BEC, considering age, asthma, COPD, and clinical allergy for the general adult population.
Methods The West Sweden Asthma Study constitutes a population-representative clinical epidemiological cohort of randomly selected adults in western Sweden. From this cohort, n=1,145 took part in clinical examinations, including e.g. skin prick testing, specific immunoglobulin E, and BEC.
Results The upper limit (95th percentile) of BEC varied by age. It ranged between 400 to 500 cells/μL in the full sample, and from 300 to 400 cells/μL in subjects without asthma, COPD, and clinical allergy (n=710). Sex, smoking, atopy, clinical allergy, obesity, asthma, COPD, diabetes, and hypertension were statistically significantly associated with higher BEC levels. However, only asthma and clinical allergy in the full sample, and obesity and diabetes in those without asthma, COPD, or clinical allergy, remained statistically significant in multiple regression analyses.
Conclusion In a population-representative sample, the upper limit of BEC in healthy adults ranged between 300 and 400 cells/μL, varying by age. Age, smoking, obesity, asthma, COPD, and clinical allergy influence BEC levels and should be considered in clinical interpretation.
Clinical Implications The upper limit of normal blood eosinophil count (BEC) in participants free from asthma, COPD, and clinical allergy ranged between 300 and 400 cells/μL depending on age. These results facilitate the interpretation of BEC in clinical practice.
Capsule summary The upper limit of normal blood eosinophil count (BEC) in healthy individuals ranged between 300 and 400 cells/μL depending on age. Determinants of BEC values include age, smoking, obesity, asthma, and clinical allergy.
Support statement The study was supported by the VBG Group Herman Krefting Foundation for Asthma and Allergy Research (Trollhättan, Sweden), Swedish Research Council (Stockholm, Sweden), the Swedish Heart-Lung Foundation (Stockholm, Sweden), the Swedish Asthma and Allergy Foundation (Stockholm, Sweden), Tampere Tuberculosis Foundation (Tampere, Finland), and ALF agreement (grant from the Swedish state under the agreement between the Swedish Government and the county councils, Sweden).
Competing Interest Statement
LL reports personal fees from ALK, AstraZeneca, Berlin Chemie, Boehringer-Ingelheim, Chiesi, GSK, Novartis, Orion Pharma and Sanofi outside the current work. SSOE reports conference-attendance related costs from Thermo Fisher Scientific outside the current work. TP reports fees for lectures and/or consulting from AstraZeneca, Chiesi, GSK, Novartis and Sanofi outside the current work. HB reports personal fees for lectures form AstraZeneca, Boehringer Ingelheim and GSK outside the current work. NIB reports personal fees for lectures and consulting from DBV Technologies and AstraZeneca outside the current work. HK reports fees for lectures and/or consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi, Covis Pharma, GSK, MedScape, MSD, Novartis, Orion Pharma and Sanofi outside the current work. The rest of the authors have no conflict of interest to declare.
Funding Statement
The study was supported by the VBG Group Herman Krefting Foundation for Asthma and Allergy Research (Trollhattan, Sweden), Swedish Research Council (Stockholm, Sweden), the Swedish Heart-Lung Foundation (Stockholm, Sweden), the Swedish Asthma and Allergy Foundation (Stockholm, Sweden), Tampere Tuberculosis Foundation (Tampere, Finland), and ALF agreement (grant from the Swedish state under the agreement between the Swedish Government and the county councils, Sweden).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants signed informed consent, and the study was approved by the regional ethics board in Gothenburg, Sweden that is a part of the National Swedish Ethical Review Authority. More information can be found at: https://etikprovningsmyndigheten.se/en/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- BEC
- blood eosinophil count
- BMI
- body mass index
- COPD
- chronic obstructive pulmonary disease
- FEV1
- forced expiratory volume in one second
- FVC
- forced vital capacity
- GINA
- Global Initiative for Asthma
- GOLD
- Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease
- ICS
- inhaled corticosteroids
- sIgE
- specific immunoglobulin E
- WSAS
- West Sweden Asthma Study
